- Details
- Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...
|
- Details
- In this LUGPA CME presentation, Dr Emmanuel Antonarakis discussed genomic profiling, germline, and somatic testing in the landscape of prostate cancer. He discusses what are germline mutations, what are somatic mutations, how common they are in prostate cancer as well as who should be tested for these mutations. Dr. Antonarakis guides the views through a genomics report, a next-generation sequenci...
|
- Details
- In a comprehensive discussion led by Charles Ryan, James Gulley delves into the role of genomic testing and immunotherapy in treating prostate cancer. Dr. Gulley emphasizes the importance of personalized treatment, highlighting studies that identify specific genomic markers like homologous recombination deficiency and mismatch repair deficiency. These markers can guide the use of targeted therapie...
|
- Details
- Reconsidering back-to-back AR-directed therapies: An interview with Maha Hussain, co-principal investigator of the PROfound study. Precision medicine and targeted therapy are possible in prostate cancer. Unmet needs have included more focused treatment and novel modes of action to counter resistance to hormonal and cytotoxic therapies. The PROfound study of the PARP inhibitor olaparib in heavily p...
|
- Details
- Charles Ryan, MD, is joined by Veda Giri, MD, Patrick Pilié, MD, and Arpit Rao, MD, MBBS, for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer. To begin, Dr. Giri discusses the need for widespread genetic testing in the clinic today. Following the May 2020 United States Federal Drug Administration (FDA) approvals of PARP inhibitors...
|
- Details
- Panagiotis Vlachostergios, MD, PhD, joins Alicia Morgans, MD, MPH, to discuss germline and somatic genetic testing and the ways in which genomic material can be integrated into clinical practice. Dr. Morgans and Dr. Vlachostergios agree that patients with metastatic disease, among others, should undergo germline genetic testing, and describe how genetic counselors can help patients make sense of g...
|
- Details
- Ken Pienta, MD, discusses the role of prostate-specific membrane antigen (PSMA) in facilitating personalized medicine as an imaging agent and selection tool for assigning patients to targeted therapy. He mentions the myriad of trials on PSMA radio-ligand therapeutics that have validated its effect in patients for metastatic prostate cancer. James Gulley, MD, Ph.D., FACS, gives an overview of genom...
|
- Details
- Charles Ryan, MD, and Veda Giri, MD discuss consensus building for germline genetic testing in prostate cancer, a relevant topic given the recent FDA approval of two PARP inhibitors. Dr. Giri reflects on results from the Philadelphia Prostate Cancer Consensus Conference held in October 2019, which sought to address some of the challenges that have arisen as testing has increased and to develop a f...
|
- Details
- Elena Castro, Wassim Abida, and Karen Knudsen discuss multiple topics regarding the use of PARP inhibitors in prostate cancer treatments. The three debate PARP response data, the functions of PARP inhibitors, the importance of androgen deprivation in the use of PARP inhibitors, and genomic testing in prostate cancer. Biographies: Karen Knudsen, Ph.D., Director, National Cancer Institute (NCI), Sid...
|
- Details
- Dan Petrylak joins Tom Keane to discuss PARP inhibition in castration-resistant prostate cancer. In this lecture, Dr. Petrylak discusses the germline DNA repair mutations involved in prostate cancer. This is a state of the art lecture establishing the rationale for the clinical trials evaluating PARP inhibitors in metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD...
|
